Stock Market Reviews

NERV (Minerva Neurosciences, Inc.) News

Get the latest news, insights, and market updates on NERV (Minerva Neurosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
  BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successf
  Nov 19, 2025 - $NERV
• Minerva Neurosciences: Q3 Earnings Snapshot
  BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Wednesday reported a loss of $2.7 million in its third quarter.
  Nov 5, 2025 - $NERV
• Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
  BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates On October 23, 2025, the Company received $80 million in gross proceeds in a private placement, before deducting fees and other expenses. The f
  Nov 5, 2025 - $NERV
• Top Midday Gainers
  Beyond Meat (BYND) said Tuesday it will increase the availability of some of its plant-protein produ
  Oct 21, 2025 - $NERV
• BC-Most Active Stocks
  HIVE Digital Technologies Ltd. 31,893,838 5.71
  Oct 21, 2025 - $NERV
• Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
  Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone’s clinical development and NDA resubmission.Further $40 million proceeds may be received in connection with cash exercise of Tranche B warrants contingent upon achievement of milestone event. With the proceeds of the financing and alignment with the FDA, Minerva is expected to be sufficiently funded through th
  Oct 21, 2025 - $NERV
• Minerva Neurosciences: Q2 Earnings Snapshot
  BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Thursday reported a loss of $3.3 million in its second quarter.
  Aug 14, 2025 - $NERV
• Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
  FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today provided business updates. FDA Discussions & Roluperidone Update The Company has had multiple interactions with th
  Aug 14, 2025 - $NERV
• Minerva Neurosciences: Q1 Earnings Snapshot
  BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Tuesday reported a loss of $3.8 million in its first quarter.
  May 13, 2025 - $NERV
• Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
  BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025. Corporate Update On March 17, 2025, we were formally notified by Nasdaq that we had regained compliance with Nasdaq Listing Rule 5550(b)(3), and as such, will continue t
  May 13, 2025 - $NERV